Apricus Targets OTC Revenue, With Long-Range Focus In Rx Markets
This article was originally published in The Tan Sheet
Executive Summary
Apricus Biosciences looks to launch OTC products formulated with its proprietary delivery technology as a short-term revenue driver while developing prescription pharmaceuticals in blockbuster markets.